Contineum Therapeutics, Inc.
CTNM
$9.63
-$0.7603-7.32%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | -- | -- | -- | -- | -- |
Gross Profit | -- | -- | -- | -- | -- |
SG&A Expenses | 4.32M | 4.40M | 4.54M | 3.47M | 3.28M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 17.90M | 18.11M | 17.05M | 12.97M | 10.94M |
Operating Income | -17.90M | -18.11M | -17.05M | -12.97M | -10.94M |
Income Before Tax | -16.04M | -15.99M | -14.57M | -10.27M | -9.01M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -16.04M | -15.99M | -14.57M | -10.27M | -9.01M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -16.04M | -15.99M | -14.57M | -10.27M | -9.01M |
EBIT | -17.90M | -18.11M | -17.05M | -12.97M | -10.94M |
EBITDA | -17.82M | -18.03M | -16.97M | -12.91M | -10.88M |
EPS Basic | -0.62 | -0.62 | -0.56 | -0.40 | -0.39 |
Normalized Basic EPS | -0.39 | -0.39 | -0.35 | -0.25 | -0.24 |
EPS Diluted | -0.62 | -0.62 | -0.56 | -0.40 | -0.39 |
Normalized Diluted EPS | -0.39 | -0.39 | -0.35 | -0.25 | -0.24 |
Average Basic Shares Outstanding | 25.90M | 25.87M | 25.82M | 25.73M | 23.36M |
Average Diluted Shares Outstanding | 25.90M | 25.87M | 25.82M | 25.73M | 23.36M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |